Ikarian Capital, LLC Avalo Therapeutics, Inc. Call Options Transaction History
Ikarian Capital, LLC
- $573 Million
- Q3 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding AVTX
# of Institutions
1Shares Held
34.6KCall Options Held
0Put Options Held
0About Avalo Therapeutics, Inc.
- Ticker AVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 9,414,100
- Market Cap $88.5M
- Description
- Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...